

December 3, 2013

## ImmunoCellular Therapeutics Expands Manufacturing Relationship with Progenitor Cell Therapy, LLC for Dendritic Cell Vaccines

### *New Process Development Improvements Intended to Ensure Phase III and Commercial Readiness*

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, LLC ("PCT"), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), for current good manufacturing practices (cGMP) services for ImmunoCellular's dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a phase I clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a Services Agreement between the companies. PCT also manufactured phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM. Under this newly executed Services Agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT will develop that can be applied to the manufacture of all ImmunoCellular's current vaccine product candidates, ICT-107, ICT-121 and ICT-140. These process improvements are intended to increase quality, consistency, efficiency, and cost-effectiveness, and support ImmunoCellular's vaccine manufacturing requirements for conducting potential phase III registration trials and for commercial manufacturing. PCT's facilities are registered with the FDA as human cells, tissues, and cellular and tissue-based products (HCT/PS) facilities, and maintain GMP-compliant quality systems.

"Ensuring that ImmunoCellular has an established manufacturing process that can support pivotal registration programs and eventual commercial manufacturing for all our dendritic cell vaccines as they advance toward registration is foundational for building a leading cancer immunotherapy company," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We look forward to continuing our partnership with PCT, and are pleased to be making this investment in process enhancements now."

#### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

#### Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107, ICT-121 and ICT-140 can be further successfully developed, manufactured or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ImmunoCellular Therapeutics, Ltd.  
Investor Relations  
Jane Green  
415-348-0010 direct  
415-652-4819 mobile  
[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

Source: ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media